TABLE 3.

Adverse events, grouped by preferred term, reported by >10% of subjects

Event(s)No. of subjects (%)Pa
Vehicle (n = 39)Resiquimod (n = 43)
At least one adverse event22 (56)25 (58)1.000
General disorders and administrative site conditions9 (23)5 (12)0.241
Application site burning5 (13)4 (9)0.730
Skin and subcutaneous tissue disorders0 (0)5 (12)0.056
Musculoskeletal and connective tissue disorders5 (13)5 (12)1.000
Nervous system disorders7 (18)11 (26)0.437
Headache not otherwise specified5 (13)7 (16)0.760
Respiratory, thoracic, and mediastinal disorders1 (3)6 (14)0.112
  • a That is, the overall P value as determined by the two-sided Fisher exact test.